Identification of Potential Drug Targets for ZYX (G7791)
Identification of Potential Drug Targets for ZYX
ZYX (zyxin-2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the Z domain family of transmembrane proteins, which are characterized by the presence of a Z-type repeats in their extracellular domain. ZYX is also a type of Z-repeat protein, which is a common structural motif found in various proteins that involves the repetition of a specific amino acid sequence.
One of the unique features of ZYX is its ability to form a monomeric species, which means that it can exist in solution as a single protein molecule. This is important for ZYX's function as a drug target, as it allows it to interact with small molecules in a controlled manner. Additionally, ZYX's monomeric state allows it to be easily purified and used for a variety of biochemical and cellular studies.
ZYX is involved in a number of cellular processes that are important for maintaining normal physiological function. For example, it is involved in the regulation of ion channels, which are responsible for the flow of electrical impulses through cells. ZYX is also involved in the regulation of cell signaling pathways, as well as in the detoxification of harmful substances.
In addition to its role in cellular signaling, ZYX is also a potential drug target. Its unique monomeric state and its involvement in a number of important cellular processes make it an attractive target for small molecules that can modulate its function. Currently, several studies are being conducted to identify potential small molecules that can interact with ZYX and modulate its function.
One of the most promising potential drug targets for ZYX is the molecule N-Acetyl-L-Tyrosine (NAT), which is a non-coding RNA molecule that has been shown to interact with ZYX. NAT is a molecule that has been shown to play a role in a variety of cellular processes, including cell signaling, and it is thought to be involved in modulating the function of ZYX.
NAT has been shown to interact with ZYX by forming a complex with the protein. This complex is stable and can be used to study the behavior of ZYX in solution. Additionally, studies have shown that NAT can modulate the function of ZYX in a variety of ways, including by modulating its stability and by altering its localization in the cell.
Another potential drug target for ZYX is the molecule Custom, which is a protein that is involved in the regulation of ion channels. Custom is thought to interact with ZYX by modulating its structure and function. This interaction between ZYX and Custom is an attractive target for small molecules that can modulate the function of ZYX.
In conclusion, ZYX is a protein that is involved in a number of important cellular processes and is a potential drug target. Its monomeric state and its involvement in cell signaling pathways make it an attractive target for small molecules that can modulate its function. The molecule N-Acetyl-L-Tyrosine (NAT) and the protein custom are currently being studied as potential drug targets for ZYX. Further studies are needed to fully understand the role of ZYX in cellular processes and its potential as a drug target.
Protein Name: Zyxin
Functions: Adhesion plaque protein. Binds alpha-actinin and the CRP protein. Important for targeting TES and ENA/VASP family members to focal adhesions and for the formation of actin-rich structures. May be a component of a signal transduction pathway that mediates adhesion-stimulated changes in gene expression (By similarity)
The "ZYX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZYX comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
